0309 GMT - Pro Medicus's proven ability to maintain a steady cadence of new contracts helps justify the imaging tech provider's premium valuation, according to its bulls at Goldman Sachs. The investment bank's analysts also see the Australia-listed company's A$24 million contract with NYU Lagone Health as evidence of the ability to upsell additional services to existing customers. They tell clients in a note that there is potential for Pro Medicus to renew or upgrade existing customers on favorable terms. GS lifts its target price 14.5% to A$221.00 and keeps a buy rating on the stock, which is up 10% at A$251.73. (stuart.condie@wsj.com)
(END) Dow Jones Newswires
November 27, 2024 22:09 ET (03:09 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。